	US 12,442,001 B2
	Double stranded RNA specifically inhibiting expression of IL-23 and pharmaceutical composition comprising same
Yasushi Miwa, Higashikagawa (JP); Hidetoshi Hamamoto, Higashikagawa (JP); and Tatsuhiro Ishida, Tokushima (JP)
Assigned to MEDRX CO., LTD., Kagawa (JP)
Appl. No. 17/916,060
Filed by MEDRx Co., Ltd., Kagawa (JP)
PCT Filed Apr. 2, 2021, PCT No. PCT/JP2021/014321 § 371(c)(1), (2) Date Sep. 30, 2022, PCT Pub. No. WO2021/201276, PCT Pub. Date Oct. 7, 2021.
Claims priority of application No. 2020-067837 (JP), filed on Apr. 3, 2020.
Prior Publication US 2023/0167448 A1, Jun. 1, 2023
Int. Cl. C12N 15/113 (2010.01); A61P 17/06 (2006.01)

CPC C12N 15/1136 (2013.01) [A61P 17/06 (2018.01); C12N 2310/11 (2013.01); C12N 2310/30 (2013.01)]

14 Claims

1. A double stranded RNA comprising a sense strand and an antisense strand, wherein each of the strands has 19 to 30 nucleotides and comprises a base sequence selected from SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6 or a complementary base sequence thereof.